Takeda: Gastroesophageal Reflux trials

The registry lists 44 Gastroesophageal Reflux studies with Takeda as lead sponsor. 0 are open to participants now and 26 have results posted.

Phase 1 7Phase 2 6Phase 3 16Phase 4 7No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"CompletedNCT03214952Results posted
• Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"CompletedNCT03214081Results posted
• Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory EvaluationCompletedNCT03116841Phase 4Results posted
• Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)CompletedNCT02954848Phase 3Results posted
• Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese PatientsCompletedNCT02873689Phase 3Results posted
• Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)CompletedNCT02743949Phase 2Results posted
• Dexlansoprazole in Asian Participants With Gastroesophageal Reflux DiseaseCompletedNCT02351960Phase 4Results posted
• Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating TabletsCompletedNCT02096458Phase 1Results posted
• Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Disease With Dyspepsia SymptomsCompletedNCT01990339Results posted
• Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in AdolescentsCompletedNCT01642615Phase 2Results posted
• Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in AdolescentsCompletedNCT01642602Phase 2Results posted
• Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)CompletedNCT01472939Phase 2Results posted
• An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD PatientsTerminatedNCT01370863Phase 2Results posted
• Safety and Efficacy of Lansoprazole in Patients With Reflux DiseaseCompletedNCT01135368Phase 4Results posted
• Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux DiseaseCompletedNCT01045096Phase 1Results posted
• Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor TherapyCompletedNCT00847808Phase 3Results posted
• Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux DiseaseCompletedNCT00847210Phase 1Results posted
• Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep DisordersCompletedNCT00830115Results posted
• Efficacy of Pantoprazole 20/40 mg Once Daily (od) in Patients Older Than 12 Years Who Have Gastrointestinal Symptoms of Reflux DiseaseCompletedNCT00829738Results posted
• A Study of Dexlansoprazole Modified Release Formulation to Treat Night HeartburnCompletedNCT00627016Phase 3Results posted
• Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders (PULS)CompletedNCT00562094Results posted
• Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD)CompletedNCT00561730Results posted
• Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux DiseaseCompletedNCT00321984Phase 3Results posted
• Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat HeartburnCompletedNCT00255190Phase 3Results posted
• Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat HeartburnCompletedNCT00251758Phase 3Results posted
• Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat HeartburnCompletedNCT00251745Phase 3Results posted
• A Study of Dexlansoprazole Modified Release (MR) in Gastroesophageal Reflux Disease (GERD) Participants in the Russian FederationWithdrawnNCT04311541
• A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years OldCompletedNCT02616302Phase 2
• Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 MonthsWithdrawnNCT02442752Phase 1
• TAK-438 - Safety, Blood Levels & Effects of Repeated DosesCompletedNCT02141711Phase 1
• Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux DiseaseCompletedNCT01474369Phase 3
• Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux DiseaseCompletedNCT01132638Phase 3
• The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)TerminatedNCT00449813Phase 4
• Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)CompletedNCT00336219Phase 3
• Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Non-erosive Reflux or Gastroesophageal Reflux Disease (BY1023/DE-004)CompletedNCT00326027Phase 3
• Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342)CompletedNCT00325676Phase 4
• The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal RefluxCompletedNCT00324974Phase 3
• Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)CompletedNCT00312806Phase 3
• Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506)CompletedNCT00261339Phase 4
• Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)CompletedNCT00261300Phase 3
• Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)CompletedNCT00246909Phase 4
• A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.CompletedNCT00220818Phase 1
• A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Gastroesophageal Reflux DiseaseCompletedNCT00174928Phase 1
• Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)CompletedNCT00163306Phase 3